Amundi FTSE MIB Daily (2x) Leveraged UCITS ETF Dist logo

Amundi FTSE MIB Daily (2x) Leveraged UCITS ETF Dist (LEVMIm)

Market Closed
CBOE CBOE
- Market Cap
- Div Yield
- Volume
Want to track LEVMIm and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LEVMIm pays dividends to its shareholders, with the most recent payment made on Dec 16, 2025.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XMIL (EUR).

Amundi FTSE MIB Daily (2x) Leveraged UCITS ETF Dist (LEVMIm) FAQ

On which exchange is it traded?

Amundi FTSE MIB Daily (2x) Leveraged UCITS ETF Dist is listed on CBOE.

What is its stock symbol?

The ticker symbol is LEVMIm.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Amundi FTSE MIB Daily (2x) Leveraged UCITS ETF Dist ever had a stock split?

No, there has never been a stock split.

Amundi FTSE MIB Daily (2x) Leveraged UCITS ETF Dist Profile

CBOE Exchange
FR Country

Overview

Intrasense SA is a pioneering company engaged in the design and development of comprehensive software solutions for advanced visualization and analysis of multimodal medical images. Operating under the well-recognized brand name Myrian, Intrasense has carved out a significant global presence. Founded in 2004, the company's headquarters are located in Montpellier, France, indicating its roots in European innovation and technological advancement. This initiative reflects Intrasense SA’s commitment to enhancing the diagnostic and investigative capabilities within the healthcare industry, leveraging cutting-edge technologies to push the boundaries of medical imaging.

Products and Services

Intrasense SA offers an extensive range of products and services developed under the Myrian brand to cater to various needs in medical imaging. These offerings are designed to improve the efficiency, accuracy, and diagnostic capabilities in healthcare settings, providing robust tools for professionals in the field.

  • Myrian Imaging Layer: A versatile multimodal visualization software platform suite tailored for the health industry. It facilitates advanced analysis across different imaging modalities, enabling comprehensive patient imaging studies.
  • Myrian Studio: This innovative solution supports the development of medical imaging applications. Targeted at innovators, industrial clients, spin-offs, and research laboratories, Myrian Studio simplifies the creation of custom imaging solutions.
  • Myrian Technologies: Dedicated to the advancement of biomarker and artificial intelligence solutions in medical imaging. These technologies are at the forefront of integrating AI to improve diagnostic processes and patient outcomes.
  • Myrian Clinical Apps: A portfolio of clinical applications for advanced post-processing, which includes:
    • Myrian XP-Breast: Focused on breast imaging analytics.
    • Myrian XP-Prostate: Offers detailed prostate imaging analysis.
    • Myrian XP-Liver: Tailored for comprehensive liver imaging studies.
    • Myrian XP-Mammo: A specialized tool for mammography analysis.
    • Myrian XP-Lung: Delivers lung imaging and analysis capabilities.
    • Myrian XP-Colon: Designed for colon imaging analytics.
    • Myrian XL-Onco: Lesion tracking solutions catering to oncology needs.
    • Myrian XP-Vessel: Aids in the analysis of vascular imaging.
    • Myrian XP-Cardiac: Provides tools for cardiovascular imaging and analysis.
    Each of these applications is built to address specific pathology or organ-related imaging requirements, leveraging MRI, CT, conventional radiology, and nuclear imaging exams for a holistic analysis approach.

Contact Information

Address: 1231, avenue du Mondial 98, Montpellier, France, 34000
Phone: 33 4 67 13 01 30